FOA Search

This funding opportunity aims to accelerate the establishment of effective and reliable biomarkers for Alzheimer's disease (AD) and AD-related dementias (ADRD), supporting analytical and/or clinical validation of biomarkers with rigor consistent with FDA regulatory pathways. The goal is to enable their use in therapy and medical product discovery, clinical development, and clinical practice.

The New Investigator Gateway Award in Type 1 Diabetes (T1D) Research provides support for innovative preliminary research projects by new and early stage investigators. This program embeds awardees within major collaborative consortia, offering them opportunities to network, deepen understanding of key questions in T1D, and form lasting research collaborations to propel their careers forward. The initiative is expected to benefit both investigators and collaborative networks by bringing in new perspectives, ideas, and fostering a robust pipeline of talent in T1D research. Clinical trials are not permitted under this R03 mechanism.

The New Investigator Gateway Awards for Collaborative T1D Research (R03) is a funding opportunity from the National Institutes of Health (NIH), specifically through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of The Director (OD). The program aims to support a robust pipeline of innovative projects and new investigators in type 1 diabetes (T1D) research, focusing on understanding T1D mechanisms, prevention, treatment, and cure. Awardees will be embedded within large, established research consortia such as HIRN, TrialNet, TEDDY, DFC, and CaRe-T1D to promote collaboration, networking, and career advancement. Clinical trials are not allowed for this opportunity. Applicants must target research topics aligned with the scientific priorities of these consortia and address key barriers in T1D research.

This NIH funding opportunity seeks to support collaborative research that leverages biosamples and/or data from type 1 diabetes clinical studies or trials to advance understanding of the disease's etiology and pathogenesis. The ultimate goal is to uncover critical disease mechanisms that help delay or prevent type 1 diabetes. Projects should utilize samples or data from rigorously characterized clinical resources such as DPT-1, TrialNet, or TEDDY, ensuring documented access consistent with NIH sharing policies. Topics of interest include biomarkers, environmental triggers, autoimmunity, mechanistic studies using multi-omics, immune activity at various disease stages, therapeutic responses (especially immune modulation), age effects, and comorbid autoimmune conditions. Non-responsive projects include those proposing use of animal models, clinical trials with efficacy endpoints, or any use of restricted samples not permitting open data/publication in accordance with NIH policy.

This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and biosamples from clinical trials and studies. The goal is to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes. Clinical trials are not allowed under this funding opportunity.

The International Research Scientist Development Award (IRSDA) (K01) provides support and protected time (3-5 years) to advanced postdoctoral U.S. research scientists and recently appointed junior faculty for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank. The goal is to help researchers develop independently funded research careers focused on global health. Applicants must propose career development activities and a research project relevant to the health priorities of the LMIC under the mentorship of both LMIC and U.S. mentors. Independent Clinical Trials are not allowed.

The International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) provides 3 to 5 years of support and protected time to advanced postdoctoral U.S. research scientists and recently-appointed junior faculty. The award aims to facilitate mentored research career development in a low- or middle-income country (LMIC), fostering the transition to an independent global health research career focusing on the LMIC's health priorities. The opportunity is designed for candidates proposing to lead an independent clinical trial, feasibility study, or ancillary trial, with strong mentoring support from both U.S. and LMIC institutions. Applicants must develop impactful research addressing scientific needs of LMICs, develop research skills, and fulfill robust institutional and mentor commitment requirements.

This funding opportunity, issued by the National Institutes of Health (NIH), aims to promote research investigating protective and pathogenic mechanisms at the nexus of mitochondrial function and aging, specifically in the context of HIV infection and exposure to addictive substances. The goal is to generate foundational knowledge that could be leveraged to develop targeted therapies and improve health outcomes for people aging with HIV, substance use, and addiction. Clinical trials are not allowed under this R01 mechanism.

This funding opportunity aims to promote research investigating protective and pathogenic mechanisms at the intersection of mitochondrial function and aging, focusing on the context of HIV infection and exposure to addictive substances. The goal is to generate foundational knowledge that can be leveraged to develop targeted therapies and improve outcomes for people aging with HIV, substance use, and addiction.

The AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Clinical Scientist Career Development Award (K08) provides an intensive, mentored research career development experience in comparative effectiveness research (CER) methods as applied to patient-centered outcomes research (PCOR). This program is designed to support qualified individuals and aims to improve healthcare outcomes based on patient perspectives.

The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program designed to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both phases are mentored, and the award supports the extramural phase to help launch competitive, independent research programs. This FOA does not allow applicants to lead independent clinical trials, clinical trial feasibility studies, or ancillary studies to clinical trials, but does allow research experience in clinical trials if the trial is led by a mentor or co-mentor.

The AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Research Scientist Career Development Award (K01) provides support to qualified individuals for an intensive, mentored research career development experience. The program focuses on comparative effectiveness research (CER) methods as applied to patient-centered outcomes research (PCOR), helping researchers develop the skills necessary for a successful independent research career.

This funding opportunity supports research and training related to hazardous substances under the Superfund Hazardous Substance Program (P42 Clinical Trial Optional). Sponsored by the National Institute of Environmental Health Sciences (NIEHS) at NIH, this grant focuses on the assessment, evaluation, and treatment of hazardous substances. The program is governed by NIEHS legislative authority and Section 311(a)(3) of SARA, emphasizing both basic research and education to address hazardous waste issues.

The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development program aimed at facilitating the timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both phases of the award involve mentorship, and research support is provided during the extramural phase to launch competitive, independent research programs. Applicants must propose to serve as lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial as part of their research and career development.

This funding opportunity, issued by the National Institutes of Health (NIH), Department of Health and Human Services, aims to support small business concerns (SBCs) in developing technologies for commercialization to address health-related social needs impacting substance use disorders (SUD), specifically excluding alcohol use disorder.

This Notice of Funding Opportunity (NOFO) invites applications to use the NIH INCLUDE Project (Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) resources to generate a large volume of integrated genomic and multi-omics data to facilitate discovery of molecular mechanisms underlying health conditions related to Down syndrome. Applicants may propose omics assays of existing biospecimens from individuals with Down syndrome and controls, utilizing techniques such as whole genome sequencing (short-read and long-read), exome, epigenome, transcriptome sequencing, proteomics, metabolomics, single-cell RNA sequencing, and ATAC sequencing when justified. All generated omics and phenotypic data will be deposited in a public INCLUDE Project controlled-access database for research community sharing. No direct funding is provided to applicants under this NOFO, but successful applicants gain access to NIH resources for data generation. Clinical trials are not permitted.

This funding opportunity supports applications from small business concerns (SBCs) to develop technologies for commercialization that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. Funded projects should create innovative solutions or products to improve the circumstances contributing to SUDs. The funding mechanism is the R43/R44 grant with clinical trial participation optional. Applications must be submitted via Grants.gov, and project aims must exclude alcohol use disorder as a focus.

The HIV Vaccine Research and Design (HIVRAD) Program supports multi-component, multi-disciplinary projects that investigate scientific questions related to AIDS prophylactic vaccine discovery research. The program allows for extensive evaluation of vaccine concepts in non-human primate models. The funding instrument is a grant, categorized as discretionary, and the program is administered by the U.S. Department of Health and Human Services through the National Institutes of Health (NIH).

This Small Research Grant (R03) supports meritorious projects that seek to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The program encourages the next generation of researchers to pursue careers in AD/ADRD research and stimulates established researchers without a major AD/ADRD award to conduct pilot studies for innovative research based on their expertise. The funding supports a wide array of topics within AD/ADRD to advance scientific understanding and interventions.

This funding opportunity, sponsored by the National Institutes of Health (NIH), aims to support doctoral candidates engaged in high-priority areas of maternal and child health by facilitating dissertation research that leverages the Environmental influences on Child Health Outcomes (ECHO) program's large, longitudinal datasets. The ECHO DASH data repository contains de-identified data from over 71,000 maternal and child participants across the U.S., focusing on environmental exposures and key pediatric outcomes such as pre-, peri-, and postnatal health, airway outcomes, obesity, neurodevelopment, and positive health. This grant enables doctoral students to analyze these data, advancing research on early environmental exposures and child health.